Journal
SMALL
Volume 14, Issue 42, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.201801905
Keywords
dual targeting; glioma treatment; LDLR; nanoparticle design; thermal therapy
Categories
Funding
- National Natural Science Foundation of China [21675032, 81573002, 81773280]
- Fundamental Research Funds for the Central Universities
- DHU Distinguished Young Professor Program
- Shanghai Pujiang Program [17PJD002]
- China Postdoctoral Science Foundation [2015M58184]
- Postdoctoral Research Funding Plan in Jiangsu Province [1601039A]
- China Postdoctoral Science Fund [57, 2015M571792]
- Jiangsu Postgraduate Innovation Plan Research Project [SJLX16_0566]
Ask authors/readers for more resources
Accumulating studies have investigated the efficacy of receptor-mediated delivery of hydrophobic drugs in glioma chemotherapy. Here, a delivery vehicle comprising polyethylene glycol (PEG) and oxidized nanocrystalline mesoporous carbon particles (OMCN) linked to the Pep22 polypeptide targeting the low-density lipoprotein receptor (LDLR) is designed to generate a novel drug-loaded system, designated as OMCN-PEG-Pep22/DOX (OPPD). This system effectively targets glioma cells and the blood-brain barrier and exerts therapeutic efficacy through both near-infrared (NIR) photothermal and chemotherapeutic effects of loaded doxycycline (DOX). Pathological tissue microarrays show an association of LDLR overexpression in human glioma tissue with patient survival.NIR irradiation treatment and magnetic resonance imaging results show that OPPD reaches the effective glioma-killing temperature in a glioma-bearing rat with a skull bone removal model and considerably reduces glioma sizes relative to the drug-loaded system without the Pep22 peptide modification and the control respectively. Thus, OPPD not only effectively targets LDLR-overexpressing glioma but also exerts a dual therapeutic effect by transporting DOX into the glioma and generating thermal effects with near-infrared irradiation to kill tumor cells. These collective findings support the utility of the novel OPPD drug-loaded system as a promising drug delivery vehicle for clinical application in glioma therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available